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Abstract
There is a global variation in the incidence of renal masses with the developed nations having a greater incidence. About 80–90% 
of renal malignancies are renal cell carcinomas (RCC) which account for 2–4% of all cancers. In Africa and the Middle East, 
the age-standardized incidence for RCC is 1.8–4.8/100,000 for males and 1.2–2.2/100,000 for females. The management of renal 
cell cancer is challenging. A multidisciplinary approach is effective for diagnosis, staging, and treatment. Guidelines recommend 
active surveillance, thermal ablation, partial nephrectomy, radical nephrectomy, cytoreductive nephrectomy and immunotherapy 
as various modalities for various stages of RCC. However, open radical nephrectomy is most widely adopted as an option for 
treatment at various stages of the disease in sub-Saharan Africa due to its cost-effectiveness, applicability at various stages, and 
the reduced cost of follow-up. Nevertheless, most patients in the region present with the disease in the advanced stage and despite 
surgery the prognosis is poor.
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Introduction
There is a global variation in the incidence of renal masses 
with the developed nations having a greater incidence (1). 
GLOBOCAN has estimated that approximately 300,000 men 
and women were diagnosed with renal cancer globally and 
nearly 150,000 renal cancer-related deaths occurred in 2012 
(2). In 2018, the global incidence was 403,262 with 175,098 
deaths reported by GLOBOCAN (3). About 80–90% of renal 
malignancies are renal cell carcinomas (RCCs) which account 
for 2–4% of all cancers (4). In Africa and the Middle East, 
the age-standardized incidence for RCC is 1.8–4.8/100,000 
for males and 1.2–2.2/100,000 for females (2). A review by 
Atanda and Haruna in 2017 estimated the incidence of RCC 
in Nigeria as approximately 0.3/100,000 of the population (5).
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The morbidity and mortality of renal malignancy have re-
duced or remained steady in developed nations, but this finding 
cannot be postulated for the disease in sub-Saharan nations. 
Major risk factors and etiologies identified include smoking, 
hypertension, obesity, and familial RCC syndrome (1). How-
ever, moderate alcohol intake and consumption of fruits and 
vegetables have proven to have a protective action (6, 7).
The management of renal cell cancer is challenging. 
A  multidisciplinary approach is effective for the diagnosis, 
staging, and treatment. Available guidelines from the Amer-
ican Urological Association (1), European Association of 
Urology (8), and Canadian Urological Association (9) show 
a consensus on partial nephrectomy, radical nephrectomy, 
anti-angiogenic/immunotherapy, and cytoreductive therapy 
as treatment options for RCC based on the staging. In 2015, 
Zekri and colleagues published a guideline for clear cell renal 
carcinoma for Middle East Countries and Africa emphasiz-
ing on a multidisciplinary board for renal malignancy due to 
the complexity of treatment options (4).
Whether the recommendations set by these guideline have 
been fully adopted into clinical practice in the sub-Saharan 
region remains unknown. It is relevant that a consensus on 
the management of renal masses is reached in a regional con-
text that is clinically applicable. We therefore present findings 
from the Western sub-Saharan nations on the management 
of RCC to stimulate a development of a regional consensus.
Methodology
A thorough search of the available literature was conducted 
by reviewing publications from 1996 to 2019 using the search 
engines PubMed, Google Scholar, African Journal Online, 
and Cochrane Library. The search terms used included 
“Management of Renal Masses” appended with the follow-
ing indices: Guidelines, Africa, Sub-Saharan Africa, Senegal, 
Liberia, Ghana, Nigeria, Burkina, Mali, Togo, Ivory Coast, 
Kenya, Uganda. There were a total of 209 study results and 
only 30 studies were included in the review. These included 
clinical guidelines, systemic reviews and meta-analysis, ran-
domized trials, prospective and retrospective studies. The re-
view considered papers dealing with adult renal tumors only. 
All pediatric renal lesions were excluded.
Eleven published papers from the sub-Saharan region were 
included for cross-tabulation of data. Both the abstracts and 
full texts were reviewed for demographics, age, gender, du-
ration of symptoms, clinical presentation, risk factors, asso-
ciated complication, diagnostic imaging modalities, tumor 
consistency, tumor size, clinical staging, histological type, 
treatment option, rate of recurrence, and outcome. The re-
sults of the literature search are reflected in Tables 1–4. A 
quantitative analysis of the data retrieved is represented in 
the main text of the results using pool analysis of age, gen-
der, duration of symptoms, and clinical presentation. The 
risk factors, complications, diagnostic modalities, and out-
comes were analyzed qualitatively as depicted in the follow-
ing section.
Results from the Retrieved Literature
There were 11 published papers from the sub-Saharan re-
gion (10–20) including Senegal, Togo, Nigeria, and Benin 
which discussed the management of  renal tumors. A total 
Table 1: Demographics, age distribution, and duration of symptoms in patients with renal cell carcinoma
Study
Number of 
patients
Gender distribution Age distribution in years
Duration of  
symptoms in months
Male (%) Female (%) Mean age Age range Mean Range
Tengue et al. (Togo) (10) 32 46.9 53.1 48.1 ± 10.8 31–75 8.6 +7.8 1–48
Fall et al. (Senegal) (11) 74 48.7 51.3 49 18–72 10 1–96
Gueye et al. (Senegal) (12) 42 51 18–83 14
Ahmed et al. (Nigeria) (13) 61 37.4 62.6 44 15–70 12 1–192
Tijani et al. (Nigeria) (14) 64 37.5 62.5 41.8 20–75
Mbaeri et al. (Nigeria) (15) 19 26.3 73.4 52.6 + 15.8 22–75
Avakoudjo et al. (Benin) (16) 46 60.9 39.1 54 19–83
Coulibaly et al. (Burkina Faso) (17) 24 41.7 58.3 48.2 ± 8.02 17–82
Muhammed et al. (Nigeria) (18) 51 33.3 66.7 43.1
Badmus et al. (Nigeria) (19) 18 61.6 38.4 47.5 16–80 43.6 2–104
Salako et al. (Nigeria) (20) 51 33.3 66.7 41.7 21–83 6–32
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of  482 cases of  renal masses were obtained from the 11 
studies (Table 1). Based on a pool analysis of  the data, 
there was a predominance of  renal masses amongst fe-
males (57.2%) as opposed to males (42.8%) in sub-Saharan 
Africa. Benin (16) and Nigeria (19) contrarily reported a 
greater male to female ratio. The mean age of  diagnosis 
was 47.4 years with an age range of  15–83 years. Pooled 
results from the reviewed data showed a mean duration of 
symptoms from onset to presentation at 17.6 months with 
a range of  1–192 months. Most published literature in West 
Africa reported flank pain, hematuria, and lumbar mass 
as the commonest clinical presentation with lumbar mass 
being highlighted in all the studies reviewed (10–17, 19, 
20). Smoking (10, 20), hypertension (10, 16, 20), obesity 
(20), family history (14), and exposure to industrial dyes 
(14) were the risk factors associated with renal malignancy 
reported from the sub-Saharan literature (Table  2). The 
data have shown that most patients in sub-Saharan Africa 
presented with locally advanced to metastatic disease. Only 
a few studies from Togo (10) and Nigeria (20) showed a 
higher percentage of  patients presenting with clinically 
 localized disease (68.8% and 47.1%, respectively). Anemia, 
varicocele, hypertension, and pleural effusion were com-
mon renal cancer-related complications reported by  Tengue 
et al. (10), Tijani et al. (14), and Salako et al. (20). His-
tological reports from sub-Saharan nations revealed that 
RCC was the commonest histological type of  cancer with 
clear cell carcinoma being the most dominant variant at an 
average of  61.6% (Table 3). The average tumor size from 
four publications (10, 11, 14, 17) was 15.1 cm with a range 
of  2.4–30 cm. An average of  74.4% of  patients presenting 
with renal masses were managed with radical nephrectomy. 
However, data from Senegal and Nigeria revealed 1.4% 
and 5.3% of  renal masses were managed with partial ne-
phrectomy. Reports from Togo (10) and Nigeria (14, 18, 20) 
mentioned the use of  immunotherapy in some patients 
with advanced disease. Sunitinib, bevacizumab, interferon 
alpha, and sorafenib were the immunotherapeutic options 
available in these studies (Table 4). A study from Senegal by 
Gueye et al. (12) reported that 40% of  patients could not 
receive treatment due to the disease being in the advanced 
stage while Tijani et al. (14), Mbaeri et al. (15), and Bad-
mus et al. (19), reported patients with unresectable tumor 
during laparotomy.
Table 2: Clinical manifestation, risk factors, complications, and diagnostics modalities of renal cell carcinoma
Study
Clinical presentation
Risk factors
Associated 
complications
Diagnostic 
modalities
Imaging  
findings of 
tumors
Flank pain 
(%)
Hematuria 
(%)
Lumbar mass 
(%)
Tengue et al. 90.6 28.1 9.3 Smoking, 
hypertension
Severe anemia CT-scan, 
ultrasound
Solid: 93.7%; 
cystic: 6.3%
Fall et al. 87.8 77
Gueye et al. 70.8 Ultrasound, 
IVU
Ahmed et al. 74.9 57.9 86
Tijani et al. 86 40.6 90 Family history, 
smoking, dyes 
exposure
Anemia, 
pedal edema, 
Varicocele
CT-Scan Solid: 100%
Mbaeri et al. 78.9 522.6 78.9 Ultrasound, 
IVU
Avakoudjo et al. 100 48.4 Hypertension Anemia, 
Varicocele
CT-scan, 
ultrasound, 
IVU
Coulibaly et al. 66.7
Badmus et al. 94.4 50.0 83.3 Anemia, pleu-
ral effusion
Ultrasound, 
IVU
Salako et al. 7.9 11.8 37.2% Hypertension, 
smoking, 
obesity
CT-scan, 
ultrasound, 
IVU
CT-scan: computed tomography scan; IVU: intravenous urography.
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Discussion of the Recommended  
Standard of Care
Diagnosis
History and physical exam are important components of 
assessing a renal mass. The relevant clinical presentation in-
cluding hematuria, flank pain, and lumbar mass should be 
ascertained. All possible risk factors or etiologies should be 
sought. Physical exam findings of  varicocele or pedal edema 
could depict vascular involvement of  the tumor or inferior 
vena cava (IVC) invasion. Though most authors reported 
the clinical triad of  RCC, the presence of  a lumbar mass 
was reported in all the studies reviewed from the sub-Saha-
ran region (10–20). A complete blood count (CBC), renal 
function (creatinine, estimated glomerular filtration rate), 
liver function (alanine transaminase, aspartate aminotrans-
ferase), and bony markers (alkaline phosphatase, calcium) 
should be evaluated (1, 9). In the presence of  an elevated 
creatinine, a renal scintigraphy should be performed to 
assess renal function. Computed tomographic scan (CT-
scan) is the imaging of  choice with about 90% accuracy for 
renal masses (Figures 1 and 2). Renal malignancy is most 
likely when contrast attenuation of  10–20 Hounsfield Unit 
(HU) is obtained for a renal mass (9). CT scan is essential 
for staging renal cancer, lymph node assessment, as well as 
identification of  metastasis. A chest CT is ideal for assessing 
metastasis when findings of  chest x-ray are equivocal. Mag-
netic resonance imaging (MRI) and Doppler ultrasound 
are useful for determining the IVC involvement. Findings 
by Tengue et al., Tijani et al., Avokoudjo et al. and Salako 
et al. highlighted the use of  CT-scan and ultrasound to 
diagnose and stage renal malignancies. The use of  intrave-
nous urogram (IVU) though limited was reported by some 
studies (12, 15, 19, 20) from the sub-Saharan region. It may 
have been useful for large tumors that may have distorted 
the renal parenchyma.
CT-scan or MRI findings of  cystic renal lesion, Bosniak 
class I and class II, have minimum risk of  malignancy and 
require no follow-up. However, Bosniak class IIF has a 10% 
risk of  malignancy and follow-up with ultrasound or CT 
is recommended. Bosniak class III and IV have 65% and 
92% risk of  malignancy respectively and require treatment 
( Figure 2) (9).
The use of renal mass biopsy is optional and should be 
performed if  the histological results will change the decision 
of the management. Renal mass biopsy is essential for pa-
tients with metastatic disease or hematological malignancy 
(lymphoma) (1) who are candidates for systemic therapy. The 
percutaneous ultrasound or CT-guided core biopsy approach 
has proven to be safe (1, 9). The sensitivity and specificity of 
renal mass biopsy for the diagnosis of renal malignancy are 
high, especially for RCC (21).
Table 3: Renal tumor size, clinical staging, and commonest histological types in sub-Saharan Africa
Study
Incidental 
finding 
(%)
Tumor 
size in 
centimeters Range
Clinical 
staging Locally 
advanced
Advanced/
metastatic
Commonest histological types
Mean Localized (%)
Tengue et al. 3.1 12.8±4.3 5–25 68.8 9.4 21.8 93.1% (clear cell RCC)
Fall et al. 2.7 12 2.4–26 T2 (39.2) T3 (33.7) 31 63.5% (RCC)
Gueye et al. 25 93% (RCC)
Ahmed et al. 30.1 63.9 60.3 59% (clear cell RCC)
Tijani et al. 1.5 22 12–30 6.3 60.9 36 60% (clear cell RCC)
Mbaeri et al. 21.1 21.1 57.8 53.8% (clear cell RCC)
Avakoudjo 
et al.
T2 (43.3) T3 (13.3) T4 (43.3) 58.8% (clear cell RCC)
Coulibaly 
et al.
13.6±5.8 7.8–21.1 40 40 95.8% (RCC)
Muhammed 
et al.
11.8 11.8 90 74.5% (clear cell RCC)
Badmus et al. 11.1 88.9 72.2% (RCC) 33% (clear cell RCC)
Salako et al. 5.9 47.1 35.3 17.6 60.8% (clear cell RCC)
RCC: renal cell carcinoma.
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Management of Localized Renal Cell Carcinoma 
(cT1-T2, N0 M0)
cT1a
It is recommended that patients with cT1a renal tumors should 
be offered partial nephrectomy as it is associated with good 
oncological outcomes and minimizes the risk of chronic kid-
ney disease (1). Partial nephrectomy or nephron sparing proce-
dures should be considered for patients with bilateral tumors, 
tumors of solitary kidney, or patients with familial renal tumor. 
However, in candidates undergoing partial nephrectomy, a 
negative surgical margin should remain a priority. More com-
plex tumors not amenable to partial nephrectomy can undergo 
radical nephrectomy. In elderly patients who are frail and can-
not withstand surgery, thermal ablation of the renal tumor is 
an option but a biopsy is required before the procedure. Active 
surveillance has been advocated for select patients but regular 
follow-up with imaging for 3–6 months is warranted.
cT1b
Tumor greater than 4 centimeters (cm) but <7 cm is amena-
ble to partial nephrectomy either open, laparoscopic, or ro-
botic as evidenced by the acceptable oncological results (9). 
When partial nephrectomy is not technically feasible, 
a laparoscopic radical nephrectomy should be consid-
ered  over open radical nephrectomy as it is associated 
with less postoperative pain and better recovery (22,  23). 
Active   surveillance has shown some benefits in selected 
patients with RCC following renal mass biopsy. Ablative 
therapy should not be considered an option in this sub-
set as complete thermal ablation is challenging in tumors 
> 4 cm (9).
cT2
Patients with renal tumor >7 cm limited to the kidney 
can  undergo open or laparoscopic radical nephrectomy 
Table 4: Treatment modalities for renal tumors and outcome of the disease and treatment in sub-Saharan Africa
Study
Treatment options
Others
Rate of 
recurrence
OutcomeRadical  
nephrectomy 
(%)
Partial  
nephrec-
tomy (%)
Anti-angiogenics
Tengue et al. 90.6 9.4% (Sunitinib) 6.9% (LND) 9.4% 28.1% (mortality)
Fall et al. 58.1 1.4 12.2% 47.3% mortality
Gueye et al. 60 40% received no Rx due 
to advanced disease
38% (1-year 
mortality)
Ahmed et al. 20 months (median 
survival)
Tijani et al. 70.3 29.6% (bevaci-
zumab, inter-
feron alpha)
4 unresectable tumors All T4 and M1 were 
dead within a year
Mbaeri et al. 57.9 5.3 1 unresectable tumor Average follow-up 
(4 months)
Avakoudjo et al. 56.5 8.7% perioperative 
mortality, most lost 
to follow-up
Coulibaly et al. 100
Muhammed et al. 100 7.8% adjuvant 
immunotherapy
90% died 
within 1-year of 
nephrectomy
Badmus et al. 72.2 11% unresectable 
tumor
7.6% mortality
Salako et al. 78.4 7.8% sunitinib/
sorafenib
LND: lymph node dissection.
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(24, 25). Extended partial nephrectomy is discouraged in 
this population (9).
It may be debatable that patients from the sub-Saharan set-
tings are offered partial nephrectomy for localized disease as 
the technique itself  has not been widely applied amongst urol-
ogists in the region. The lack of resources, cost of active sur-
veillance, and the loss to follow-up of most patients in these 
settings render the nephron-sparing procedure less desirable. 
Radical nephrectomy may provide a better oncological result 
though the risk of chronic kidney disease is not eliminated.
Management of Locally Advanced Renal Cell 
Carcinoma (T1-T2, N1, M0 or T3, N0/N1, M0)
T3
Approximately 4–10% of  RCCs will involve the IVC (9, 
26). Tumors >7 cm that have not invaded the Gerota fascia 
but involve the IVC are managed with radical nephrectomy 
and thrombectomy as this approach has provided accept-
able morbidity in the absence of  metastasis (9, 26). When 
there is an upper pole tumor, ipsilateral involvement of 
the adrenal gland intraoperatively or following imaging, 
an ipsilateral adrenalectomy is ideal as 1.9–7.5% of  renal 
malignancy will involve the ipsilateral adrenal gland (27). 
Routine regional lymphadenectomy is not recommended in 
localized disease but patients with clinical (N1, M0) dis-
ease are candidates for regional lymph node dissection. The 
role of  neoadjuvant and adjuvant therapy for RCC remains 
unclear.
The evidence has shown that most patients in sub-Saharan 
Africa present with locally advanced to metastatic disease 
(11–19). Open radical nephrectomy has been well adopted for 
locally advanced disease in Africa. Evidence from published 
literature in the region has shown that an average of 74.4% 
of patients presenting with renal masses were managed with 
radical nephrectomy. A 16-year retrospective study by Ten-
gue et al. (10) in Togo involving 32 patients with RCC who 
underwent surgery showed that 6.9% of patients required 
lymph node dissection.
Treatment of Advanced Disease (T4 N0/N1 M0)
T4
Surgical resection is the only available treatment option for 
T4 tumors. These tumors are best managed in high-volume 
centers with resection of the ipsilateral adrenal gland and 
part of the liver, pancreas, or diaphragm if  required (9). Most 
of these patients already have occult lymph node involvement 
Figure 1: A contrast coronal CT-scan showing a hyper vascu-
larized right T4 renal tumor found to have affected the renal 
vein, IVC, and inferior margin of the liver.
Figure 2: A contrast CT-scan showing a cystic right renal 
tumor in the upper pole with associated hydronephrosis. 
Courtesy: Grand Yoff Hospital.
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which demands regional lymph node dissection. Despite 
these gestures, the 5-year overall survival is poor, and the 
surgical morbidity of extensive resection should be weighed 
against the oncological benefits (28, 29).
Studies by Tijani et al. (14) and Muhammed et al. (18) from 
Nigeria showed a poor prognosis of T4 disease despite inter-
vention with an overall 1-year disease survival of less than 10%.
Treatment of Metastatic Disease  
(Any T, Any N + M1)
Cytoreductive nephrectomy is recommended in patients 
with metastatic disease. Studies have provided better re-
sults when nephrectomy is combined with systemic therapy 
as compared to systemic therapy alone (30). Cytoreductive 
nephrectomy and interferon alpha help to improve survival 
rates in patients with RCC (8). In well-selected patients, 
metastasectomy following nephrectomy has given good re-
sults. Metastasis to the pancreas, lungs, bone, and adrenal 
gland has a more favorable prognosis (9). Radiotherapy to 
a local or distant site of  metastasis (brain, bone) in pa-
tients with RCC can relieve pain. Chemotherapy plays a 
limited role as a systemic therapy in RCC, especially clear 
cell metastatic RCC. However, Gemcitabine, 5- Fluoroura-
cil, and Doxorubicin have some documented effect (8).
Immunotherapy
Data have shown that interferon alpha and Bevacizumab 
increase the response rate and progression free survival in 
metastatic RCC compared to interferon alpha alone (8). 
 Ipilimumab plus nivolumab in treatment-naïve patients with 
clear cell RCC provide a better survival rate compared to 
sunitinib (8). These drugs are associated with significant side 
 effects and should be administered by a multidisciplinary 
team.
The use of systemic therapy following cytoreductive ne-
phrectomy in patients with advanced or metastatic RCC is 
not well-documented in West Africa. However, a few studies 
from Togo (10) and Nigeria (14, 18, 20) documented the use 
of immunotherapy in some patients with advanced disease. 
Sunitinib, bevacizumab, interferon alpha, and sorafenib were 
the available immunotherapeutic options for these studies. 
A study by Muhammed et al. documented that 4 (7.8%) 
patients who had adjuvant treatment (immunotherapy or 
vascular endothelial growth factor (VEGF)-tyrosine kinase 
inhibitors) had a better prognosis (18). The management of 
advanced and metastatic disease was not well-documented 
in the review from sub-Saharan nations. Moreover, most of 
the institutions lack the recommended immunotherapeutic 
agents or rather referred the patients to medical oncology for 
further management. It is important that urologists and on-
cologists from sub-Saharan Africa coordinate with relevant 
pharmaceutical companies for provision or supply of these 
agents at an affordable cost.
Follow-up
Post-surgical follow-up should be based on individual risk 
assessment. Low-risk patients should have imaging (CT, 
MRI, or ultrasound) performed within a year following sur-
gery. Chest X-ray should be performed yearly for the first 
3–6 years to check for metastasis. Moderate- to high-risk 
patients will require an MRI or CT-scan 6 months after sur-
gery. A yearly chest X-ray or chest CT-scan is advisable for 
up to 5 years.
Outcome
Data from the review showed heterogenous results on the 
perioperative mortality following radical nephrectomy in the 
sub-Saharan region. However, analysis of reports from Nige-
ria (14, 19), Togo (16), and Mali (17) showed a perioperative 
mortality of 5.1% following radical nephrectomy. Most of 
these deaths were due to perioperative hemorrhage or pul-
monary complications. These data are comparable to the re-
sults of a systemic review of RCC in Nigeria which showed a 
perioperative mortality of radical nephrectomy ranging from 
6.3% to 7.8% (5). These figures are much higher than the 
perioperative mortality of radical nephrectomies in Europe 
and North America which is about 2.8% (5). The late pa-
tient presentation, the lack of expertise for nephron sparing 
procedures, and the underequipped intensive care unit have 
contributed to this dismal result. However, more funding, 
quality imaging, and diagnostics as well as human expertise 
are required for uro-oncological care in the region with pro-
motion of a multidisciplinary approach. Urologists, medical 
oncologists, radio-oncologists, and radiologists should com-
municate to provide the best standard of care and adopt a 
guideline that is practical, feasible but evidence based. This is 
only achievable through proper documentation and coordi-
nated research in the  African context.
Extrapolation of  the 5-year overall survival of  RCC fol-
lowing treatment is challenging as the reportings are heter-
ogenous. Nevertheless, a retrospective review of  61 patients 
with RCC in Nigeria had a 5-year survival of  46% for 
young adults and 26% for older adults using the Kaplan–
Meier analysis (13). Another contemporary series in Nige-
ria showed a lower 5-year survival of  RCC of  less than 10% 
following radical nephrectomy (18). Better cancer-aware-
ness programs, maintaining an effective cancer-treatment 
guideline, and establishing a cancer registry in the sub-re-
gion are required to achieve 5-year overall survival rates 
of  55% and 73% as obtained from Europe and the United 
States, respectively (5).
Conclusion
The management of  renal cell cancer is challenging. A 
multidisciplinary approach is effective for diagnosis, stag-
ing, and treatment. Active surveillance, thermal ablation, 
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 partial nephrectomy, radical nephrectomy, cytoreductive 
nephrectomy, and immunotherapy are being recommended 
as various modalities by guidelines for various stages of 
RCC. However, open radical nephrectomy is most widely 
adopted as a treatment option at various stages of  the 
disease in sub-Saharan Africa due to its cost-effective-
ness, applicability at various stages, and the reduced cost 
of   follow-up. Nevertheless, most patients present with ad-
vanced disease in the region and despite surgery the prog-
nosis is poor.
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